The Lysosomal Storage Disorders Support Society has petitioned for emergency funding after over 160 patients exhausted the ₹50 lakh coverage limit under the National Policy for Rare Diseases. This funding crisis directly affects patient access to critical therapies and highlights the challenges of balancing government health budgets with the high costs of long-term care for rare metabolic disorders.
The Lysosomal Storage Disorders Support Society has formally urged the central government to release interim funding for patients suffering from rare genetic metabolic disorders. The request follows a critical situation where the existing ₹50 lakh financial assistance limit, mandated under the National Policy for Rare Diseases, has been exhausted by at least 164 patients. With funds depleted, at least 115 patients—many diagnosed with conditions such as Gaucher and Pompe disease—are currently unable to access the specialized enzyme replacement therapies necessary for their survival.
From a policy perspective, this crisis underscores a structural challenge within India's rare disease management framework. The National Policy for Rare Diseases, launched in 2021, was designed to centralize and streamline support for ultra-rare conditions. However, the implementation of a fixed financial cap per patient has created a scenario where, once a specific spending threshold is met, the government’s liability effectively ends. For patients with conditions requiring lifelong, continuous medication, this creates a sudden and severe interruption in care.
The pharmaceutical and healthcare sector closely monitors these policy developments because the market for orphan drugs—medicines designed for rare diseases—is heavily dependent on government-backed procurement and subsidy schemes. Due to the extremely high cost of these therapies, private insurance penetration remains low, and out-of-pocket expenditure is often prohibitive for the average family. Consequently, government policy acts as the primary driver of demand for these high-value medical products. When funding gaps emerge, it creates operational uncertainty for manufacturers and distributors operating in this niche segment, as consistent therapy intake is essential for drug demand.
Medical advocacy groups emphasize that these therapies are not curative in a short-term sense but require consistent administration to maintain clinical gains. Any interruption, they argue, results in a regression of health, essentially wasting the expenditure already incurred by the state. The society is currently seeking humanitarian intervention while the broader legal matter is addressed in the Supreme Court.
For stakeholders in the healthcare ecosystem, the situation highlights the complexity of creating sustainable funding models for high-cost, rare disease treatments. The next important monitorable will be whether the government introduces a supplementary funding mechanism or modifies the existing policy to ensure continuity of care for patients who have already crossed the current financial threshold.